Cargando…

Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine

Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver with high morbidity and mortality rates worldwide. Since 1963, when alpha-fetoprotein (AFP) was discovered as a first HCC serum biomarker, several other protein biomarkers have been identified and introduced into clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Moldogazieva, Nurbubu T., Mokhosoev, Innokenty M., Zavadskiy, Sergey P., Terentiev, Alexander A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914649/
https://www.ncbi.nlm.nih.gov/pubmed/33562077
http://dx.doi.org/10.3390/biomedicines9020159
_version_ 1783657052846948352
author Moldogazieva, Nurbubu T.
Mokhosoev, Innokenty M.
Zavadskiy, Sergey P.
Terentiev, Alexander A.
author_facet Moldogazieva, Nurbubu T.
Mokhosoev, Innokenty M.
Zavadskiy, Sergey P.
Terentiev, Alexander A.
author_sort Moldogazieva, Nurbubu T.
collection PubMed
description Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver with high morbidity and mortality rates worldwide. Since 1963, when alpha-fetoprotein (AFP) was discovered as a first HCC serum biomarker, several other protein biomarkers have been identified and introduced into clinical practice. However, insufficient specificity and sensitivity of these biomarkers dictate the necessity of novel biomarker discovery. Remarkable advancements in integrated multiomics technologies for the identification of gene expression and protein or metabolite distribution patterns can facilitate rising to this challenge. Current multiomics technologies lead to the accumulation of a huge amount of data, which requires clustering and finding correlations between various datasets and developing predictive models for data filtering, pre-processing, and reducing dimensionality. Artificial intelligence (AI) technologies have an enormous potential to overcome accelerated data growth, complexity, and heterogeneity within and across data sources. Our review focuses on the recent progress in integrative proteomic profiling strategies and their usage in combination with machine learning and deep learning technologies for the discovery of novel biomarker candidates for HCC early diagnosis and prognosis. We discuss conventional and promising proteomic biomarkers of HCC such as AFP, lens culinaris agglutinin (LCA)-reactive L3 glycoform of AFP (AFP-L3), des-gamma-carboxyprothrombin (DCP), osteopontin (OPN), glypican-3 (GPC3), dickkopf-1 (DKK1), midkine (MDK), and squamous cell carcinoma antigen (SCCA) and highlight their functional significance including the involvement in cell signaling such as Wnt/β-catenin, PI3K/Akt, integrin αvβ3/NF-κB/HIF-1α, JAK/STAT3 and MAPK/ERK-mediated pathways dysregulated in HCC. We show that currently available computational platforms for big data analysis and AI technologies can both enhance proteomic profiling and improve imaging techniques to enhance the translational application of proteomics data into precision medicine.
format Online
Article
Text
id pubmed-7914649
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79146492021-03-01 Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine Moldogazieva, Nurbubu T. Mokhosoev, Innokenty M. Zavadskiy, Sergey P. Terentiev, Alexander A. Biomedicines Review Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver with high morbidity and mortality rates worldwide. Since 1963, when alpha-fetoprotein (AFP) was discovered as a first HCC serum biomarker, several other protein biomarkers have been identified and introduced into clinical practice. However, insufficient specificity and sensitivity of these biomarkers dictate the necessity of novel biomarker discovery. Remarkable advancements in integrated multiomics technologies for the identification of gene expression and protein or metabolite distribution patterns can facilitate rising to this challenge. Current multiomics technologies lead to the accumulation of a huge amount of data, which requires clustering and finding correlations between various datasets and developing predictive models for data filtering, pre-processing, and reducing dimensionality. Artificial intelligence (AI) technologies have an enormous potential to overcome accelerated data growth, complexity, and heterogeneity within and across data sources. Our review focuses on the recent progress in integrative proteomic profiling strategies and their usage in combination with machine learning and deep learning technologies for the discovery of novel biomarker candidates for HCC early diagnosis and prognosis. We discuss conventional and promising proteomic biomarkers of HCC such as AFP, lens culinaris agglutinin (LCA)-reactive L3 glycoform of AFP (AFP-L3), des-gamma-carboxyprothrombin (DCP), osteopontin (OPN), glypican-3 (GPC3), dickkopf-1 (DKK1), midkine (MDK), and squamous cell carcinoma antigen (SCCA) and highlight their functional significance including the involvement in cell signaling such as Wnt/β-catenin, PI3K/Akt, integrin αvβ3/NF-κB/HIF-1α, JAK/STAT3 and MAPK/ERK-mediated pathways dysregulated in HCC. We show that currently available computational platforms for big data analysis and AI technologies can both enhance proteomic profiling and improve imaging techniques to enhance the translational application of proteomics data into precision medicine. MDPI 2021-02-06 /pmc/articles/PMC7914649/ /pubmed/33562077 http://dx.doi.org/10.3390/biomedicines9020159 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Moldogazieva, Nurbubu T.
Mokhosoev, Innokenty M.
Zavadskiy, Sergey P.
Terentiev, Alexander A.
Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine
title Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine
title_full Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine
title_fullStr Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine
title_full_unstemmed Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine
title_short Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine
title_sort proteomic profiling and artificial intelligence for hepatocellular carcinoma translational medicine
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914649/
https://www.ncbi.nlm.nih.gov/pubmed/33562077
http://dx.doi.org/10.3390/biomedicines9020159
work_keys_str_mv AT moldogazievanurbubut proteomicprofilingandartificialintelligenceforhepatocellularcarcinomatranslationalmedicine
AT mokhosoevinnokentym proteomicprofilingandartificialintelligenceforhepatocellularcarcinomatranslationalmedicine
AT zavadskiysergeyp proteomicprofilingandartificialintelligenceforhepatocellularcarcinomatranslationalmedicine
AT terentievalexandera proteomicprofilingandartificialintelligenceforhepatocellularcarcinomatranslationalmedicine